Stockreport

Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) [Yahoo! Finance]

Beam Therapeutics Inc.  (BEAM) 
PDF On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 [Read more]